Form 4: Tourmaline Bio CEO Kulkarni Acquires Shares in Open Market
SEC Form 4 Filing
Tourmaline Bio CEO Sandeep Chidambar Kulkarni reports the acquisition of 5,221 shares of common stock at an average price of $13.79.
Summary
- On August 16, 2024, Sandeep Chidambar Kulkarni, CEO of Tourmaline Bio, Inc., acquired 5,221 shares of common stock.
- The shares were purchased at a weighted average price of $13.79, with individual transactions ranging from $13.77 to $13.79.
- Kulkarni also indirectly owns shares through Gilead Capital, LP, where his spouse is a partner with shared voting and investment power.
Sentiment
Score: 6
Explanation: Neutral sentiment. The document simply reports a transaction. The CEO's purchase could be seen as a positive signal, but without further context, it's difficult to gauge the overall impact.
Positives
- The CEO's purchase of shares may signal confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure of insider trading activity, which is common for executives of publicly traded companies. It provides transparency into the trading activities of key personnel.
Stakeholder Impact
- The CEO's share purchase could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/16/2024 | Date of the transaction: CEO purchased shares of common stock. |
| 08/20/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.